RVMD · Revolution Medicines

The thesis

Revolution Medicines' shares are more likely than not to lag the S&P 500 over the next three months. They closed at $176.35 on 12 November 2026, below the $177.65 close of 5 November 2026 that followed third-quarter results, and the fourth-quarter report, expected in about February 2027, shows whether the first quarter's RASONQUE sales were repeatable.

The $180.00 kill line was crossed on 12 November 2026, when the shares closed at $176.35. The line was set to test the case that the shares would lead after results. The close showed that case failing: the shares rose to $200.15 on 9 November 2026, then closed at $193.06, $180.70 and $176.35 on the next three sessions. The Nasdaq 100 rose 2.8% on 11 November 2026, the day the shares fell to $180.70.

What the price reflects: at $176.35, the shares sit at the level of the first session after the report, so the $197.6 million of third-quarter RASONQUE (daraxonrasib) sales against a $23.5 million analyst estimate no longer shows in the price. The company said that figure included one-time patient conversions and pharmacy stocking and should not be read as the longer-term trajectory.

Bullish and bearish views on Revolution Medicines, Inc.

The bull case on Revolution Medicines, Inc. (RVMD), in brief: launch revenue far exceeded estimates. The bear case: third-quarter sales included one-time effects.

Bull case

• Launch revenue far exceeded estimates. Benzinga reported on 4 November 2026 that third-quarter sales were $197.559 million against a $23.495 million estimate, with a loss of $1.90 per share against $2.42 expected. A third-party review (finsee.ai) says more than 5,000 commercial patients were treated in about five weeks.
• Analysts raised targets after the report. HC Wainwright's target is $350 as of 6 November 2026. On 5 November 2026 Evercore ISI's target moved to $340, RBC's to $321, Guggenheim's to $298, TD Cowen's to $270, Truist's to $261 and Piper Sandler's to $222.
• Efficacy data are strong. In the Phase 3 RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib against 6.7 months with chemotherapy (hazard ratio 0.40), per OncLive on 15 October 2026. The European Medicines Agency's committee recommended marketing authorisation the same day.
• Cash is large. Cash and marketable securities were $3,651 million at 30 September 2026, per finsee.ai. A $250.0 million drawdown from Royalty Pharma followed on 8 October 2026.

Bear case

• Third-quarter sales included one-time effects. The company said the quarter should not be read as indicative of the longer-term trajectory, per finsee.ai. The review attributes part of the revenue to patients moving from the free access program, waiting patients and pharmacy stocking. Management gave no fourth-quarter revenue outlook.
• Spending is rising fast. Third-quarter operating expenses were $570.7 million, up 81% from a year earlier, and the net loss was $407.5 million, per finsee.ai. Full-year operating-expense guidance of $2.15–2.2 billion was unchanged.
• G12D patients responded less often. FDA review documents showed a 32% overall response rate, 50% in G12V patients and 24% in G12D patients, who were 43% of the population, GuruFocus reported on 8 October 2026. The FDA said the analyses were not designed for subgroup comparisons.
• Insiders keep selling. SEC Form 4 filings show Anthony Mancini sold 811 shares at $200.00 on 9 November 2026 and 2,310 shares at $186.99 on 26 October 2026, both under Rule 10b5-1 plans (pre-scheduled sale plans). Chief Development Officer Alan Sandler sold 6,309 shares at an average of $202.14 on 29 September 2026.
• The share count grew. Diluted shares rose 13.6% to 214.9 million in the third quarter, per finsee.ai, after the company sold 10,563,381 shares at $142.00 each on 14 April 2026 (SEC Form 424B5).

Price setup

The shares closed at $176.35 on 12 November 2026. That is below the 50-day average of $195.24 and above the 200-day average of $159.51. The three-month change is −13.4%, measured from the $203.71 close of 14 August 2026.

The 52-week intraday high is $224.31 on 27 August 2026, and the last close is 21.4% below it. The 52-week closing low is $64.38 on 13 November 2025. The 8 October 2026 intraday low of $180.52 was the nearest recent floor; the shares closed below it on 12 November 2026.

Headlines on 12 November 2026 reported that the FDA suspended a fast-track drug review initiative during a leadership vacuum. The approval of RASONQUE on 26 August 2026 is already granted, and no change to its label has been reported.

Catalysts ahead

• Not yet announced: European Commission decision on RASONQUE marketing authorisation. A positive decision opens the European launch that the company is building with its own sales force; no decision date has been published.
• ~February 2027 (est.): Fourth-quarter 2026 results and call. First report that shows whether RASONQUE sales hold after one-time patient conversions and pharmacy stocking in the third quarter.

What would change the view

A daily close above $200.00, which would retrace the whole decline from the 9 November 2026 close of $200.15 and show the shares leading again; or fourth-quarter RASONQUE sales above the $197.6 million third-quarter level.

The line before it, a daily close below $180.00 set on 7 November 2026, was crossed on 12 November 2026: the shares closed at $176.35.

What it trades with

RVMD trades with high-growth biotech, so rising interest rates and falling small-cap indexes weigh on it independent of launch progress. On 8 October 2026 the 10-year Treasury yield was near 5.35% and small caps lagged, per Benzinga. On 11 November 2026 the Nasdaq 100 rose 2.8% while RVMD closed at $180.70, down from $193.06 the session before, so the decline came apart from the broad market.

Within oncology, the shares react to RAS-inhibitor news from competitors and to the Erasca litigation over ERAS-0015, filed 27 April 2026 and unresolved.